Index S&P 500
P/E 61.68
EPS (ttm) 2.72
Insider Own 0.11%
Shs Outstand 1.77B
Perf Week 2.16%
Market Cap 297.12B
Forward P/E 13.81
EPS next Y 12.15
Insider Trans -19.17%
Shs Float 1.77B
Perf Month -6.01%
Income 4.82B
PEG 9.73
EPS next Q 2.26
Inst Own 71.78%
Short Float 0.77%
Perf Quarter 2.18%
Sales 54.32B
P/S 5.47
EPS this Y 0.12%
Inst Trans 0.10%
Short Ratio 2.42
Perf Half Y 15.94%
Book/sh 5.87
P/B 28.60
EPS next Y 9.23%
ROA 3.52%
Short Interest 13.54M
Perf Year 2.27%
Cash/sh 7.24
P/C 23.18
EPS next 5Y 6.34%
ROE 34.90%
52W Range 130.96 - 182.89
Perf YTD 8.28%
Dividend Est. 6.23 (3.71%)
P/FCF 13.49
EPS past 5Y -5.77%
ROI 7.61%
52W High -8.25%
Beta 0.58
Dividend TTM 6.06 (3.61%)
Quick Ratio 0.76
Sales past 5Y 11.76%
Gross Margin 70.40%
52W Low 28.13%
ATR (14) 3.20
Dividend Ex-Date Apr 12, 2024
Current Ratio 0.87
EPS Y/Y TTM -59.03%
Oper. Margin 37.04%
RSI (14) 44.01
Volatility 1.64% 1.84%
Employees 50000
Debt/Eq 5.80
Sales Y/Y TTM -6.44%
Profit Margin 8.87%
Recom 2.00
Target Price 184.49
Option/Short Yes / Yes
LT Debt/Eq 5.11
EPS Q/Q -67.09%
Payout 220.33%
Rel Volume 0.71
Prev Close 169.54
Sales Surprise 1.97%
EPS Surprise -0.11%
Sales Q/Q -5.42%
Earnings Apr 26 BMO
Avg Volume 5.60M
Price 167.80
SMA20 -1.70%
SMA50 -4.12%
SMA200 7.31%
Trades
Volume 4,074,765
Change -1.03%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-29-24 Upgrade
William Blair
Mkt Perform → Outperform
Dec-18-23 Downgrade
HSBC Securities
Buy → Hold
Dec-11-23 Upgrade
Goldman
Neutral → Buy
Nov-09-23 Initiated
Deutsche Bank
Hold
$150
Oct-30-23 Upgrade
Barclays
Equal Weight → Overweight
$160 → $170
Oct-20-23 Resumed
UBS
Neutral
$157 → $150
Sep-29-23 Initiated
Raymond James
Outperform
$177
Jul-25-23 Initiated
William Blair
Mkt Perform
Jul-14-23 Initiated
HSBC Securities
Buy
$167
Apr-05-23 Downgrade
Argus
Buy → Hold
Mar-01-23 Initiated
Guggenheim
Buy
$172
Feb-22-23 Downgrade
Wolfe Research
Outperform → Peer Perform
Feb-10-23 Upgrade
SVB Securities
Underperform → Market Perform
$135 → $153
Nov-18-22 Initiated
Credit Suisse
Outperform
$170
Nov-08-22 Downgrade
Societe Generale
Buy → Hold
Aug-01-22 Downgrade
Atlantic Equities
Overweight → Neutral
$178 → $162
May-23-22 Initiated
SVB Leerink
Underperform
$140
May-06-22 Downgrade
Daiwa Securities
Outperform → Neutral
$150
Apr-06-22 Resumed
Morgan Stanley
Overweight
$192
Feb-28-22 Downgrade
UBS
Buy → Neutral
$129 → $147
Show Previous Ratings
Apr-23-24 03:09PM
12:38PM
12:14PM
09:15AM
08:00AM
12:56PM
Loading…
Apr-22-24 12:56PM
09:47AM
Apr-21-24 07:00AM
Apr-19-24 04:11PM
(Investor's Business Daily)
10:00AM
Apr-18-24 03:44PM
12:18PM
(The Wall Street Journal)
08:31AM
06:30AM
Apr-17-24 05:45PM
10:21AM
Loading…
Apr-16-24 10:21AM
10:01AM
09:00AM
08:00AM
03:06AM
03:02AM
Apr-15-24 07:57AM
07:43AM
Apr-14-24 01:23AM
Apr-13-24 12:18PM
Apr-12-24 04:19PM
07:30AM
Apr-11-24 05:45PM
07:02AM
Apr-10-24 10:53AM
08:00AM
Loading…
Apr-09-24 08:00AM
07:13AM
04:21AM
Apr-08-24 05:50PM
09:19AM
Apr-06-24 06:49AM
Apr-05-24 05:45PM
09:00AM
08:00AM
06:39AM
Apr-04-24 06:52PM
08:00AM
Apr-03-24 08:48AM
08:30AM
Apr-02-24 12:41PM
10:28AM
08:00AM
03:36AM
Apr-01-24 05:45PM
07:50AM
04:30AM
Mar-31-24 11:52AM
Mar-30-24 05:19AM
Mar-29-24 12:16PM
Mar-28-24 01:38PM
Mar-27-24 10:00AM
Mar-26-24 10:03AM
08:36AM
06:18AM
04:56AM
Mar-25-24 05:45PM
01:27PM
12:58PM
12:40PM
11:45AM
11:00AM
09:25AM
09:00AM
08:39AM
08:37AM
08:31AM
08:05AM
Mar-24-24 03:54PM
11:04AM
Mar-22-24 07:00PM
03:10PM
03:02PM
02:35PM
Mar-21-24 10:25AM
10:00AM
08:00AM
Mar-19-24 05:45PM
08:32AM
08:00AM
08:00AM
Mar-17-24 08:15AM
Mar-14-24 09:38AM
08:18AM
Mar-13-24 05:45PM
08:17AM
06:30AM
Mar-12-24 01:20PM
09:00AM
08:33AM
08:09AM
Mar-11-24 06:21PM
04:25PM
(Investor's Business Daily)
09:28AM
Mar-10-24 10:18AM
10:00AM
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Mar 20 '24 Sale 176.30 21,082 3,716,757 55,903 Mar 22 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Option Exercise 61.36 26,110 1,602,110 119,890 Mar 20 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Sale 178.79 58,949 10,539,508 60,941 Mar 20 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Option Exercise 61.36 45,700 2,804,152 89,517 Mar 05 05:30 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Sale 177.27 75,680 13,415,503 13,837 Mar 05 05:30 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Option Exercise 58.30 21,560 1,257,012 167,524 Mar 01 05:50 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Sale 176.45 68,879 12,153,957 98,645 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 29 '24 Sale 177.39 9,891 1,754,555 10,397 Mar 01 05:50 PM Buckbee Kevin K SVP, CONTROLLER Feb 29 '24 Sale 176.65 5,144 908,688 6,983 Mar 01 05:50 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Feb 28 '24 Sale 177.27 138,616 24,572,458 519,099 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Option Exercise 137.36 13,753 1,889,115 41,926 Feb 27 05:10 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Option Exercise 61.36 14,140 867,630 41,205 Mar 01 05:50 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Sale 177.44 14,140 2,509,002 27,065 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Sale 177.51 13,753 2,441,295 28,173 Feb 27 05:10 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Option Exercise 58.88 52,870 3,112,986 296,814 Feb 23 05:00 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Sale 173.71 52,870 9,184,048 243,944 Feb 23 05:00 PM Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Dec 26 '23 Sale 154.72 2,912 450,545 55,903 Dec 28 05:00 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Aug 01 '23 Sale 148.58 60,000 8,914,800 565,294 Aug 02 05:07 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Jul 31 '23 Sale 149.15 18,500 2,759,275 625,294 Aug 02 05:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite